- Drugs Made In America Acquisition II Corp. (DMII) consummated its initial public offering (IPO) of **50,000,000 units** at **$10.00 per unit**, generating **$500,000,000** in gross proceeds on **September 26, 2025**.  **[2040475_0001213900-25-095513_ea0259662-8k_drugs2.htm:1]** **[2040475_0001213900-25-095513_ea025966201ex99-1_drugs2.htm:2]** 
- Simultaneously, the company completed a private placement of **1,200,000 units** at **$10.00 per unit**, raising an additional **$12,000,000**.  **[2040475_0001213900-25-095513_ea0259662-8k_drugs2.htm:1]** **[2040475_0001213900-25-095513_ea025966201ex99-1_drugs2.htm:2]** 
- As of **September 26, 2025**, **$500,000,000** of the net proceeds from the IPO and private placement were deposited into a trust account for the benefit of public shareholders.  **[2040475_0001213900-25-095513_ea0259662-8k_drugs2.htm:1]** **[2040475_0001213900-25-095513_ea025966201ex99-1_drugs2.htm:3]** 
- The company, a blank check company incorporated on August 23, 2024, intends to focus on the **pharmaceutical industry** for its business combination and has **24 months** from the IPO closing to complete it.  **[2040475_0001213900-25-095513_ea025966201ex99-1_drugs2.htm:2]** **[2040475_0001213900-25-095513_ea025966201ex99-1_drugs2.htm:6]** 
- The independent registered public accounting firm, MaloneBailey, LLP, issued an opinion on the financial statements that included a **going concern matter** due to the company's reliance on completing a business combination within a prescribed period.  **[2040475_0001213900-25-095513_ea025966201ex99-1_drugs2.htm:0]**

Drugs Made In America Acquisition II Corp. Completes IPO and Private Placement

- Drugs Made In America Acquisition II Corp. (DMII) priced its initial public offering of **50,000,000 units** at **$10.00 per unit** on September 25, 2025.  **[2040475_0001213900-25-093224_ea025896901ex99-1_drugs2.htm:0]** 
- The IPO closed on September 26, 2025, generating **$500,000,000** in gross proceeds before deducting underwriting discounts and offering expenses.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** **[2040475_0001213900-25-093224_ea0258969-8k_drugs2.htm:1]** 
- Concurrently with the IPO closing, the company closed a private placement of **1,200,000 private placement units** at **$10.00 per unit**, resulting in gross proceeds of **$12,000,000**.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** 
- A total of **$500,000,000** from the proceeds of the initial public offering and the private placement has been deposited into a trust account.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** **[2040475_0001213900-25-093224_ea0258969-8k_drugs2.htm:1]** 
- The units began trading on The Nasdaq Global Market under the ticker symbol **DMIIU** on September 25, 2025.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** **[2040475_0001213900-25-093224_ea025896901ex99-1_drugs2.htm:0]**

Drugs Made In America Acquisition II (DMII)